Alphamab and 3D Medicines Out-License PD-L1 to India’s Glenmark

Jiangsu Alphamab Biopharma and its partner 3D Medicines of Beijing announced an out-licensing agreement for their approved subcutaneous injection PD-L1 inhibitor, envafolimab, with Glenmark Specialty SA (GSSA) of India. GSSA will have exclusive rights to develop, register, commercialize envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America. In 2021, envafolimab was the global-first subcutaneous injection PD-L1 inhibitor approved. It was indicated as a second-line therapy for microsatellite instability-high (MSI-H) or deficient MisMatch repair (dMMR) solid tumors. Over 30,000 patients in China been treated with envafolimab. More details....

Share this with colleagues: